The Scientific Advisory Board of Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, has just met in Paris. At that meeting, the Advisory Board reviewed the various investigations under way and recommended future development directions and stages.
Pierre Corvol, Chairman of Quantum Genomics' Scientific Advisory Board, said:
“This latest meeting of the Scientific Advisory Board has been especially productive and offers further prospects for developing a range of drug programs, particularly by broadening the upcoming clinical trials in Europe and the United States using a multicentric approach.”
The Scientific Advisory Board discussed broadening the scope of the next clinical trials in Europe and the United States to adopt a multicentric approach, for both high blood pressure (QGC001 program) and heart failure (QGC101 program).
Research would be carried out simultaneously by recognized investigators located at different centers but using common protocols and identical procedures. The multicentric approach would combine as many patients as possible to obtain more accurate medical data. The keys would be:
- Defining specific patient groups
Ultimately, the goal is to define specific patient groups, to identify the most appropriate treatments for those patients. Therapeutic options will be based on the biological characteristics (markers) or genetic of given groups of patients.
- Selection of top-rank clinical investigators in Europe and the United States
As part of broadening the scope of its clinical trials, the Scientific Advisory Board has also offered the Company its help to select the centers of excellence in the most prestigious teaching hospitals with influential clinicians actively involved in the research fields concerned.
To speed its development of heart failure treatments, Quantum Genomics has set itself the goal of launching a Phase IIa clinical trial in humans by mid-2016.
With this in mind, Prof Faiez Zannad, recruited as the leading expert to develop the programme and set up clinical trials, has submitted the main features of the programme to the Scientific Committee, backed by Dr Olivier Madonna, Medical Director of Quantum Genomics. It focuses on identifying the best patient typology for this first study, the appropriate protocol, and European hospitals recognized for their expertise and groundbreaking methodology in clinical trials for this disease, that are able to quickly recruit potential patients.
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
Twitter : @QuantumGenomics - LinkedIn : Quantum Genomics
Chairman & Chief Executive Officer
+33 1 85 34 77 77
CFO – Investor Relations
+33 1 85 34 77 75
ACTUS finance et communication
01 53 67 36 73
Communiqués au titre de l'obligation d'information permanente :
- Autres communiqués
Full and original press release in PDF:
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|QUANTUM GENOMICS||Euronext Paris||3.17 (c)||-3.65%||169 705|